PE20030445A1 - Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma - Google Patents
Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la mismaInfo
- Publication number
- PE20030445A1 PE20030445A1 PE2002000922A PE2002000922A PE20030445A1 PE 20030445 A1 PE20030445 A1 PE 20030445A1 PE 2002000922 A PE2002000922 A PE 2002000922A PE 2002000922 A PE2002000922 A PE 2002000922A PE 20030445 A1 PE20030445 A1 PE 20030445A1
- Authority
- PE
- Peru
- Prior art keywords
- aripiprazole
- hydrate
- low hygroscopicity
- refers
- preparation
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004372 aripiprazole Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000012907 medicinal substance Substances 0.000 title 1
- 238000001228 spectrum Methods 0.000 abstract 2
- -1 2,3-DICHLOROPHENYL Chemical class 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A ARIPIPRAZOL 7-{4-[4-(2,3-DICLOROFENIL)-1-PIPERAZINIL]-BUTOXI}-3,4-DIHIDROCARBOESTIRILO O 7-{4-[4-(2,3-DICLOROFENIL)-1-PIPERAZINIL]-BUTOXI}-3,4-DIHIDRO-2(1H)-QUINOLONA. HIDRATO A DE ARIPIPRAZOL QUE PRESENTA UN ESPECTRO DE DIFRACCION DE RAYOS X EN POLVO CARACTERISTICO CON PICOS EN 20 IGUAL A 12.6°; 15,4°; 17,3°; 18,0°; 18,6°; 22,5° Y 24,8° Y BANDAS DE ABSORCION INFRARROJA PARTICULARES EN 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, 784 cm-1 EN EL ESPECTRO DE IR (KBr) Y UNA CURVA ENDOTERMICA CARACTERISTICA. EL HIDRATO A DE ARIPIPRAZOL TIENE UN TAMANO DE PARTICULA MEDIA DE 50 um. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION QUE COMPRENDE LA TRITURACION DEL HIDRATO CONVENCIONAL POR MEDIO DE UN ATOMIZADOR CON UNA VELOCIDAD DE ROTACION DE 5000-15000 rpm, UNA ROTACION DE ALIMENTACION DE 10-30 rpm Y UN TAMANO DE ORIFICIO DE CRIBA DE 1-5 mm. SE REFIERE TAMBIEN A CRISTALES DE ANHIDRIDO DE ARIPIPRAZOL B ENTRE OTROS QUE TIENEN BAJA HIGROSCOPICIDAD. LA INVENCION PROVEE FORMAS DE ARIPIPRAZOL DE BAJA HIGROSCOPICIDAD Y PROCESOS PARA PREPARARLAS, LAS CUALES NO SE CONVERTIRAN EN UN HIDRATO NI PERDERAN SU SOLUBILIDAD ORIGINAL
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001290645 | 2001-09-25 | ||
| JP2001348276 | 2001-11-14 | ||
| CA 2379005 CA2379005A1 (en) | 2001-09-25 | 2002-03-27 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030445A1 true PE20030445A1 (es) | 2003-07-26 |
Family
ID=36049773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000922A PE20030445A1 (es) | 2001-09-25 | 2002-09-20 | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP3081216A1 (es) |
| KR (2) | KR100530731B1 (es) |
| CN (12) | CN103191118A (es) |
| AR (3) | AR073111A2 (es) |
| CA (1) | CA2713466C (es) |
| CL (1) | CL2010000405A1 (es) |
| CY (4) | CY1110070T1 (es) |
| DK (1) | DK1925308T3 (es) |
| ES (1) | ES2596354T3 (es) |
| HK (5) | HK1203060A1 (es) |
| IL (3) | IL204707A (es) |
| LT (1) | LT1925308T (es) |
| MY (1) | MY138669A (es) |
| NO (1) | NO337844B1 (es) |
| PE (1) | PE20030445A1 (es) |
| PH (1) | PH12014500782A1 (es) |
| PL (7) | PL393607A1 (es) |
| PT (1) | PT1925308T (es) |
| RU (1) | RU2279429C2 (es) |
| SI (1) | SI1927357T1 (es) |
| TW (2) | TWI318572B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004285448C1 (en) * | 2003-10-23 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| KR102128883B1 (ko) * | 2019-10-02 | 2020-07-01 | (주)삼화바이오팜 | 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JP2608788B2 (ja) | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP3638447B2 (ja) * | 1998-09-10 | 2005-04-13 | 積水ハウス株式会社 | 笠木取付金具および笠木取付構造 |
| GB9930061D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Quinolone compounds for use in treating viral infections |
| MXPA02007035A (es) * | 2000-01-20 | 2002-12-13 | Eisai Co Ltd | Compuesto ciclico conteniendo nitrogeno y composicion farmaceutica conteniendo el compuesto. |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| JP4197088B2 (ja) | 2000-06-05 | 2008-12-17 | 電気化学工業株式会社 | 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法 |
| JP2002193915A (ja) * | 2000-12-28 | 2002-07-10 | Otsuka Pharmaceut Co Ltd | ベンゼンスルフォナート化合物 |
-
2002
- 2002-09-20 PE PE2002000922A patent/PE20030445A1/es active IP Right Grant
- 2002-09-20 MY MYPI20023512A patent/MY138669A/en unknown
- 2002-09-23 TW TW091121771A patent/TWI318572B/zh not_active IP Right Cessation
- 2002-09-23 TW TW098116881A patent/TWI332839B/zh not_active IP Right Cessation
- 2002-09-25 PL PL393607A patent/PL393607A1/pl unknown
- 2002-09-25 CN CN2013100996412A patent/CN103191118A/zh active Pending
- 2002-09-25 RU RU2004126636/04A patent/RU2279429C2/ru not_active IP Right Cessation
- 2002-09-25 PL PL393596A patent/PL393596A1/pl not_active Application Discontinuation
- 2002-09-25 EP EP16169141.5A patent/EP3081216A1/en not_active Withdrawn
- 2002-09-25 CN CN201410053619.9A patent/CN103751093A/zh active Pending
- 2002-09-25 PT PT80003585T patent/PT1925308T/pt unknown
- 2002-09-25 PL PL393603A patent/PL221536B1/pl unknown
- 2002-09-25 KR KR10-2004-7007990A patent/KR100530731B1/ko not_active Expired - Fee Related
- 2002-09-25 PL PL393608A patent/PL219564B1/pl unknown
- 2002-09-25 CN CN201310191361.4A patent/CN103288727B/zh not_active Expired - Lifetime
- 2002-09-25 SI SI200230906T patent/SI1927357T1/sl unknown
- 2002-09-25 CN CN201610186509.9A patent/CN105832677A/zh active Pending
- 2002-09-25 LT LTEP08000358.5T patent/LT1925308T/lt unknown
- 2002-09-25 CN CN201510615759.5A patent/CN105267151A/zh active Pending
- 2002-09-25 CN CN201410466919.XA patent/CN104306337A/zh active Pending
- 2002-09-25 PL PL393598A patent/PL221521B1/pl unknown
- 2002-09-25 CN CN2012100054661A patent/CN102579446A/zh active Pending
- 2002-09-25 KR KR10-2003-7000818A patent/KR100490222B1/ko not_active Expired - Lifetime
- 2002-09-25 ES ES08000358.5T patent/ES2596354T3/es not_active Expired - Lifetime
- 2002-09-25 CN CN201310728318.7A patent/CN103755632B/zh not_active Expired - Fee Related
- 2002-09-25 CN CN201410053920.XA patent/CN103751119A/zh active Pending
- 2002-09-25 PL PL417178A patent/PL230869B1/pl unknown
- 2002-09-25 CN CN201410468156.2A patent/CN104306374A/zh active Pending
- 2002-09-25 CA CA2713466A patent/CA2713466C/en not_active Expired - Lifetime
- 2002-09-25 DK DK08000358.5T patent/DK1925308T3/en active
- 2002-09-25 CN CN201410053617.XA patent/CN103751118A/zh active Pending
- 2002-09-25 CN CN201510333215.XA patent/CN104945321A/zh active Pending
- 2002-09-25 PL PL393601A patent/PL219565B1/pl unknown
-
2004
- 2004-04-22 HK HK15103617.0A patent/HK1203060A1/xx unknown
- 2004-04-22 HK HK15103616.1A patent/HK1203059A1/xx unknown
- 2004-04-22 HK HK16111449.6A patent/HK1223043A1/zh unknown
-
2009
- 2009-08-21 AR ARP090103228A patent/AR073111A2/es not_active Application Discontinuation
-
2010
- 2010-03-24 IL IL204707A patent/IL204707A/en not_active IP Right Cessation
- 2010-04-23 CL CL2010000405A patent/CL2010000405A1/es unknown
- 2010-06-11 CY CY20101100531T patent/CY1110070T1/el unknown
- 2010-06-11 CY CY20101100530T patent/CY1110212T1/el unknown
- 2010-06-11 CY CY20101100529T patent/CY1110208T1/el unknown
- 2010-07-05 CY CY20101100614T patent/CY1110244T1/el unknown
- 2010-07-05 AR ARP100102387A patent/AR077635A2/es not_active Application Discontinuation
-
2012
- 2012-08-15 AR ARP120102986A patent/AR087544A2/es not_active Application Discontinuation
-
2013
- 2013-04-23 IL IL225902A patent/IL225902A0/en unknown
-
2014
- 2014-04-08 PH PH12014500782A patent/PH12014500782A1/en unknown
- 2014-09-22 IL IL234770A patent/IL234770A0/en unknown
- 2014-10-06 NO NO20141193A patent/NO337844B1/no not_active IP Right Cessation
-
2015
- 2015-11-13 HK HK15111240.8A patent/HK1210468A1/xx unknown
-
2016
- 2016-03-23 HK HK16103439.5A patent/HK1215397A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sajjad et al. | Photoinduced fabrication of zinc oxide nanoparticles: Transformation of morphological and biological response on light irradiance | |
| WO2007079139A3 (en) | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| WO2010144464A3 (en) | Solid dispersions containing an apoptosis-promoting agent | |
| WO2001058412A3 (de) | Extrakte von rückständen aus der weinherstellung | |
| WO2007084221A3 (en) | Methods and apparatus for identifying subject matter in view data | |
| PE20030445A1 (es) | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma | |
| Yadav et al. | Antiproliferative activity of Camellia sinensis mediated silver nanoparticles on three different human cancer cell lines | |
| TR201004346T2 (tr) | Depresyon ve anksiyetenin tedavisinde farmasötikal kompozisyonlar. | |
| Trifković et al. | Chitosan crosslinked microparticles with encapsulated polyphenols: Water sorption and release properties | |
| NO20033318L (no) | 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav | |
| AU2003224482A1 (en) | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | |
| AU2002347360A1 (en) | Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours | |
| Krishna et al. | Phytochemical analysis of silver nanoparticles of Zingiber officinale and evaluation for its antibacterial property | |
| Badrillah et al. | Silver nanoparticles biogenically synthesised using Maclurodendron porteri extract and their bioactivities | |
| BRPI0408415A (pt) | processo para a preparação de uma composição particulada flavorizante ou de fragráncia sólida | |
| JP2005342578A (ja) | フッ素吸着剤、および製造方法 | |
| WO2003061684A3 (en) | Tumour treatment compositions comprising hsp70 and tumour necrosis factor | |
| IL311661A (en) | A compound and method for the prevention and treatment of skin radiation injury | |
| Soliman et al. | Novel trimetallic (TiO2–MgO–Au) nanoparticles: Biosynthesis, characterization, antimicrobial, and anticancer activities | |
| AR112440A1 (es) | Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen | |
| WO2011081280A3 (en) | Novel glucokinase activators and processes for the preparation thereof | |
| WO2006103638A3 (en) | Topical pharmaceutical compositions of terbinafine and processes for their preparation | |
| Toni et al. | In vitro role of biosynthesized nanosilver from Allium sativum against helminths | |
| WO2007066200A3 (en) | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | |
| Kanwal et al. | Innovative Extraction Techniques for Maximizing Antioxidant Yield from Moringa Stenopetala Leaf: A Step Towards Sustainable Pharmaceutical Development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration |